Tecentriq (Atezolizumab)
Tecentriq is a PD-L1 inhibitor. It is commonly used with Avastin (bevacizumab) as a first-line treatment for eligible people with advanced hepatocellular carcinoma.
Explore this therapy:
AI Summary Atezolizumab plus bevacizumab or durvalumab plus tremelimumab are the preferred first-line immunotherapy options for advanced hepatocellular carcinoma with preserved liver function.
Immunotherapy
Medically reviewed.
Immunotherapy for liver cancer is a group of prescription medicines that help the immune system recognize and attack cancer cells. The medicines used for hepatocellular carcinoma (HCC) are immune checkpoint inhibitors. They block signals, such as PD-1, PD-L1, and CTLA-4, that hold immune cells back and let cancer hide from them. Blocking these signals restores T-cell activity against the cancer and helps the immune system recognize tumors. This can help slow cancer growth, and some people have lasting responses. Immunotherapy is a systemic treatment, which means it works throughout the body. A healthcare professional gives it by IV infusion. Providers typically consider it for advanced or unresectable HCC, meaning cancer that cannot be removed with surgery.
This page explains how immunotherapy works, who may be considered for it, and what to expect during treatment. You can also connect with a liver specialist to discuss whether immunotherapy fits your care plan.
On this page
Liver Health AI Assistant
Ask Aimy
Turn confusion into a better next question.
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
IMMUNOTHERAPY OVERVIEW
What Is Immunotherapy and Who May Benefit?
Immunotherapy is a systemic treatment, which means it works throughout the body. For liver cancer, it uses immune checkpoint inhibitors: medicines that block the signals cancer uses to hide from immune cells. Treatment plans are personalized based on the stage of the cancer, liver function, overall health, and individual needs.
You can explore the five immunotherapy medicines used for hepatocellular carcinoma below. Because the right choice depends on your diagnosis and health history, a liver specialist can help you understand which option fits your care plan.
Imfinzi (Durvalumab)
Imfinzi is a PD-L1 inhibitor used for unresectable hepatocellular carcinoma. It may be used alone or with Imjudo (tremelimumab).
Explore this therapy:
Imjudo (Tremelimumab)
Imjudo is a CTLA-4 inhibitor used together with Imfinzi for unresectable hepatocellular carcinoma. It is commonly given as part of the STRIDE regimen.
Explore this therapy:
Opdivo (Nivolumab)
Opdivo is a PD-1 inhibitor used for advanced hepatocellular carcinoma. Your provider may consider it when the cancer cannot be treated with surgery or local therapies.
Explore this therapy:
Keytruda (Pembrolizumab)
Keytruda is a PD-1 inhibitor used for advanced hepatocellular carcinoma. Your provider may consider it when the cancer has progressed despite previous therapy.
Explore this therapy:
Who may benefit
Providers typically consider immunotherapy for people with advanced or unresectable hepatocellular carcinoma who need systemic treatment and are candidates for checkpoint inhibitor therapy. "Unresectable" means the cancer cannot be removed with surgery.
LIFESTYLE SUPPORT
How Daily Habits Support Immunotherapy
Immunotherapy works best when you keep your appointments and tell your care team about new symptoms early. Nutrition and hydration are part of staying well during long-term treatment.
Nutrition and hydration
Maintaining balanced nutrition and hydration is an important part of care during immunotherapy.
Infusion and monitoring visits
Attend every scheduled infusion and monitoring appointment so your care team can track how you are doing.
Report symptoms promptly
Tell your care team about cough, shortness of breath, severe fatigue, jaundice (yellowing of the skin or eyes), persistent diarrhea, or rash. These may signal immune-related inflammation.
Support your diet during treatment
A nutrition bar designed for liver health can be a simple, consistent way to support your eating habits. Ask your care team what fits your plan.
Explore Liver Health Nutrition Bars
Connect with a liver specialist to discuss whether immunotherapy fits your care plan.
HOW IMMUNOTHERAPY IS USED
Immunotherapy Regimens for Advanced Liver Cancer
Immunotherapy is used when liver cancer is advanced or cannot be removed with surgery. Your provider chooses a medicine or combination based on your cancer, your liver function, and your treatment history.
For people with advanced HCC (BCLC stage C) and preserved liver function, the preferred first-line options are atezolizumab plus bevacizumab or durvalumab plus tremelimumab.
Atezolizumab plus bevacizumab
Tecentriq is commonly combined with Avastin (bevacizumab) as a first-line treatment for eligible people with advanced HCC. First-line means the first medicine tried.
Durvalumab plus tremelimumab (STRIDE)
Imjudo is used with Imfinzi as the STRIDE regimen for unresectable HCC. The two medicines block different checkpoints, CTLA-4 and PD-L1, to strengthen the immune response. Imfinzi may also be used alone.
Nivolumab
Opdivo blocks the PD-1 pathway to restore T-cell activity against cancer cells. It is used as long-term systemic therapy in advanced HCC.
Pembrolizumab
Keytruda also blocks PD-1. It is used for advanced HCC, including when the cancer has progressed despite previous therapy.
TREATMENT MONITORING
Monitoring Your Health During Immunotherapy
Regular monitoring helps your care team see how the cancer is responding and catch immune-related side effects early. Immune-related inflammation can affect organs such as the liver, lungs, intestines, or thyroid.
Blood tests
Liver function tests track how your liver is doing during treatment and help flag changes early.
Treatment response
Your care team regularly checks how the cancer is responding. Treatment continues as long as it helps and side effects stay manageable.
Side effect check-ins
Common side effects include fatigue, rash or itching, diarrhea, and decreased appetite. Report cough, shortness of breath, jaundice, or persistent diarrhea right away.
Only a qualified healthcare provider can adjust your treatment plan based on your test results and health history.
COMMON QUESTIONS
Answers to Common Immunotherapy Questions
What is immunotherapy used for in liver cancer?
Immunotherapy for liver cancer is a group of prescription medicines that help the immune system recognize and attack cancer cells. The medicines used for hepatocellular carcinoma are immune checkpoint inhibitors, which block PD-1, PD-L1, or CTLA-4 signals. They are used for advanced or unresectable disease. Talk with your liver specialist to see whether this therapy fits your treatment plan.
How does immunotherapy work?
Immunotherapy blocks checkpoint signals that keep immune cells from attacking cancer. This restores T-cell activity and helps the immune system recognize tumors. Because it is a systemic treatment, it works throughout the body. Your healthcare provider can explain how this applies to your condition.
Which immunotherapy medicines are used for liver cancer?
Five medicines are covered in this section: Tecentriq (atezolizumab), Imfinzi (durvalumab), Imjudo (tremelimumab), Opdivo (nivolumab), and Keytruda (pembrolizumab). Tecentriq and Imfinzi block PD-L1. Opdivo and Keytruda block PD-1. Imjudo blocks CTLA-4. Each has its own page with details.
Who may be considered for immunotherapy?
Providers typically consider immunotherapy for people with advanced or unresectable hepatocellular carcinoma who need systemic treatment and are candidates for checkpoint inhibitor therapy. For advanced HCC with preserved liver function, the preferred first-line options are atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Only your healthcare provider can decide which approach is right for you.
How is immunotherapy given, and how long does it last?
A healthcare professional prepares and gives these medicines by IV infusion. Treatment usually continues until the cancer progresses, side effects become unacceptable, or your provider decides to stop. Duration varies widely and can range from several months to multiple years in people who benefit. Your care team sets the schedule for your regimen.
What are the common side effects of immunotherapy?
The most common side effects are fatigue, rash or itching, diarrhea, and decreased appetite. Immunotherapy can also cause immune-related inflammation in organs such as the liver, lungs, intestines, or thyroid. Report cough, shortness of breath, severe fatigue, jaundice, persistent diarrhea, or rash promptly. Your care team monitors you regularly and can help manage side effects.
Is immunotherapy always combined with other medicines?
Sometimes. Imfinzi may be used alone or with Imjudo. Tecentriq is commonly paired with Avastin, and Imjudo is used with Imfinzi. Your provider chooses the regimen based on your cancer, liver function, and health history.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.